A Clinical Trial on the Efficacy of a Combination Herbal Product, Biotropics' Nu Femme, on Menopausal Symptoms and Quality of Life in Women

Menopausal Symptoms Clinical Trial

— 14NMHB  

Official title:

A Randomized Double-Blind, Placebo-Controlled, Parallel Clinical Trial on the Efficacy of a Combination Herbal Product, Biotropics' Nu Femme, on Menopausal Symptoms and Quality of Life in Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02269891
• Other study ID #: 14NMHB
• Status: Completed
• Phase: Phase 2
• Start date: October 2014
• Est. completion date: September 27, 2018

Study information

• Verified date: November 2018
• Source: KGK Science Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the effectiveness of an herbal combination product called Nu Femme, on menopausal symptoms in peri-menopausal women.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 119
• Est. completion date: September 27, 2018
• Est. primary completion date: September 27, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 40 Years to 55 Years

Eligibility

Inclusion Criteria:

• Female of any race between the ages of 40 and 55 years (inclusive)

• Experiencing perimenopause (irregular menstrual cycles (>3 months) or cessation of menstrual period for at least 3 months within the last 12 months) OR women in menopause (cessation of menstrual period for at least 12 months).

• Peri-menopausal women must have an endometrial stripe < 8 mm by ultrasound at screening and menopausal women must have an endometrial stripe < 5 mm. Not required for subjects without an intact uterus.

• Women with an intact cervix must have a pap smear that is normal within 12 months of screening.

• Experiences menopausal transition symptoms such as hot flushes, sweating, sleep disturbance, migraine, anxiety, vaginal dryness and sexual problems.

• Minimum of 4 hot flashes per day or 28 per week

• Total scores of Menopause Rating Scale =17 indicating the menopausal symptoms are moderate or severe

• TSH screening to exclude undiagnosed hyperthyroidism

• Willingness and ability to give written informed consent and willingness and ability to understand, to participate and to comply with the study requirements.

Exclusion Criteria:

• Women with a positive mammogram

• Significant cardiac history including uncontrolled hypertension (defined as untreated systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg) or current diagnosis of any major diseases of the cardiovascular, hepatic, renal, gastrointestinal, pulmonary or endocrine systems

• Uncontrolled hyperlipidemia

• History or current diagnosis of breast cancer or breast cancer in an identical twin, or any cancer (except non-melanomatous skin cancer) diagnosed less than 5 years prior to randomization. Subjects with other cancers in full remission more than 5 years after diagnosis are acceptable with the exceptions of breast cancer or genital organ cancer (e.g., cervical cancer, uterine cancer, endometrial cancer, or ovarian cancer)

• Uncontrolled diabetes (Type I or Type II)

• Uncontrolled and/or untreated thyroid disorder

• History or current diagnosis of any major diseases of the cardiovascular, hepatic, renal, gastrointestinal, pulmonary or endocrine systems

• History or current diagnosis of autoimmune conditions, immunodeficiency or gynaecological disease

• Clinically significant mental depression that is not well-controlled in the opinion of the investigator

• Subject has undergone major surgery within the past one year prior to the randomization visit, except cholecystectomy, and appendectomy

• Subject smokes more than 15 cigarettes a day

• History of alcohol or drug abuse within the past year

• Subject has demonstrated non-compliance with treatment while enrolled in other experimental protocols to which the Investigator has knowledge

• Subject has a mental disability or significant mental illness, legal incapacity or limited legal capacity or any other lack of fitness, in the Investigator's opinion, to preclude subject's participation in or to complete the study

• History or findings of undiagnosed abnormal vaginal bleeding within the previous two years prior to the randomization visit, including conditions that, in the Investigator's opinion are likely to be the source of unpredictable vaginal bleeding (i.e. leiomyoma or endometrial polyps)

• Subject has uterine fibroids (> 2cm) or endometriosis. This assessment will be based on the size of the uterus of each participant and will be assessed by the Qualified Investigator

• Pregnant, breastfeeding, or planning to become pregnant during the course of the trial

• Positive urine pregnancy test result

• Polycystic ovary syndrome (PCOS)

• History of abnormal Pap smear

• Significant abnormal liver function as defined as AST and/or ALT > 2 x the upper limit of normal (ULN), and/or bilirubin > 2 x the ULN

• eGFR <60

• Bleeding disorders or anaemia of any etiology defined as haemoglobin = 110 g/L

• Subject has taken any of the following medications in the time periods specified prior to the screening visit and during the study

Sex hormones:

Vaginal rings and vaginal creams, ointments or gels 1 week Transdermal or topical 4 weeks DHEA within 24 weeks Natural supplements advertised to have hormonal effects within 4 weeks Oral within 4 weeks Intrauterine progestin implants within 8 weeks Progestin implants and estrogen alone injections within 12 weeks Injected progestin and estrogen or androgen implants or pellets within 24 weeks

Gonadotropin-releasing hormone (GnRH) agonists within 24 weeks

Selective Estrogen Receptor Modulators (SERMs) within 4 weeks

Glucocorticoids - Chronic high dose (= 7.5 mg prednisone per day or equivalent) for the past 12 weeks. Exceptions: Chronic low dose corticosteroid use (< 7.5 mg prednisone per day, or equivalent) is permitted provided the subject has been stabilized on a dose for at least 12 weeks prior to randomization and maintains the current dose and dosing regimen during the study. Acute topical, inhaled, or oral (e.g. dose packs) use is not exclusionary and will be permitted during the course of the study.

Antidepressant and/or antianxiety medications within 4 weeks unless a chronic stable dose has been maintained for greater than 12 weeks. Subject must maintain current dose and dosing regimen during the study. Use of Effexor (Venlafaxine HCl) within 4 weeks is exclusionary. Use of Dixarit (Clonidine HCl) within 2 weeks is exclusionary.

Thyroid or anti-epileptic medications within 12 weeks unless a chronic stable dose has been maintained for greater than 12 weeks prior to randomization. Subjects must maintain current dose and dosing regimen during the study

Use of Prostaglandins within 4 weeks

Other investigational study medications within 4 weeks

Current use of propranolol

Current use of an intrauterine device (IUD)

Use of natural health products, such as primrose oil, black cohosh, soy products, other than vitamin and/or mineral supplements within 4 weeks

• Known allergy or hypersensitivity to study product ingredients

• Subjects on a weight reduction program or a medically supervised diet.

• Unexplained weight loss or weight gain of more than 5 kg in the month prior to randomization

• Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject

Related Conditions & MeSH terms

• Menopausal Symptoms

Intervention

Dietary Supplement:
• Nu Femme
Combination product of Labisia pumila and Eurycoma longifolia extracts

Other:
• Placebo

Locations

Country	Name	City	State
Canada	Manna Research - Quebec	Levis	Quebec
Canada	KGK Synergize Inc.	London	Ontario
Canada	Manna Research - Montreal	Pointe Claire	Quebec
Canada	Manna Research - Toronto	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
KGK Science Inc.	Biotropics Malaysia Berhad

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Bone markers	NTX and BSALP	Baseline to week 12
Other	Blood safety parameters	CBC, electrolytes (Na K CL), glucose, creatinine, BUN, AST, ALT, GGT, bilirubin, Ca, albumin	Baseline to week 12
Other	Pap smear	Histological analysis for abnormal cells	Baseline to week 12
Other	Pelvic ultrasound	To determine changes in endometrial thickness	Baseline to week 12
Other	Incidence of adverse events		Baseline to week 12
Primary	Frequency and severity of hot flashes	Assessed based on hot flash symptoms score	Baseline to week 12
Secondary	Frequency and severity of joint pain	Assessed based on joint pain symptoms score	Baseline to week 12
Secondary	Frequency and severity of hot flashes	Assessed based on hot flash symptoms score	Baseline to week 24
Secondary	Frequency and severity of hot flashes	Assessed based on hot flash symptoms score	Week 12 to week 24
Secondary	Frequency and severity of joint pain	Assessed based on joint pain symptoms score	Baseline to week 24
Secondary	Frequency and severity of joint pain	Assessed based on joint pain symptoms score	Week 12 to week 24
Secondary	Health related quality of life	Assessed using the Menopause Rating Scale (MRS)	Baseline to weeks 3, 6, 12 and 24
Secondary	Menopause specific quality of life	Assessed using the Menopause Specific Quality of Life questionnaire (MENQOL)	Baseline to weeks 3, 6, 12 and 24
Secondary	Serum hormone concentrations	Estradiol-17b, FSH, LH, total testosterone and free testosterone	Baseline to week 12
Secondary	Serum Lipid Profile	Total cholesterol, HDL-C, LDL-C and triglycerides	Baseline to week 12